Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation

Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation

2024.03.20
In September 2023, a study led by professor Erlie Jiang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published in Hematological Oncology,  focused on the effectiveness of azacytidine (AZA) maintenance therapy post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML). Through propensity score matching, the research compared 78 treated patients with 102 historical controls, revealing that AZA significantly improves relapse-free survival without severe adverse effects. This study, by demonstrating the potential of AZA maintenance to reduce relapse in AML patients, marks a significant contribution to the field of hematological oncology and opens new avenues for personalized post-transplant care.
The Composite Immune Risk Score predicts overall survivalafter allogeneichematopoietic stem cell transplantation: A retrospective analysis of 1838 cases

The Composite Immune Risk Score predicts overall survivalafter allogeneichematopoietic stem cell transplantation: A retrospective analysis of 1838 cases

2024.03.20
In November 2022, professor Erlie Jiang and his team from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published a crucial study in the American Journal of Hematology,  focusing on the impact of the Composite Immune Risk Score on survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Analyzing 1838 cases, the study highlighted the score's potential to predict overall survival, offering a new tool for personalized post-transplant care. This research marks a significant advancement in understanding and managing hematological malignancies, promising to improve patient outcomes.
Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature

Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature

2024.03.20
In December 2023, professor Erlie Jiang and  team from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published an influential study in Frontiers in Immunology, detailing the challenges of managing refractory cytomegalovirus (CMV) infections in Chinese patients after allogeneic hematopoietic cell transplantation (allo-HCT). With a focus on China's unique position in the global context of allo-HCT and the specific difficulties faced by patients with haploidentical donors, this review underscores the urgent need for standardized care protocols. Jiang's work, through its comprehensive analysis of existing literature, significantly advances our understanding of CMV management post-transplant, aiming to improve patient outcomes and establish effective treatment guidelines. This study marks a critical step forward in optimizing post-transplant care to enhance patient survival and quality of life amidst CMV infection challenges.
Outcomes of acute myeloid leukemia patients undergoing allogeneichematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system

Outcomes of acute myeloid leukemia patients undergoing allogeneichematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system

2024.03.19
In February 2024, professor Erlie Jiang and colleagues from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published a pivotal study in Experimental Hematology & Oncology , focusing on the validation and enhancement of the 2022 European LeukemiaNet (ELN) genetic risk system for acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation. By analyzing 600 AML patients, the study not only validated the ELN-2022 system against its 2017 version but also improved its prognostic accuracy by incorporating minimal residual disease (MRD) status. This research marks a significant advancement in the personalized treatment planning and prognosis of AML patients
Comparison of autologous,matched sibling,andalternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study

Comparison of autologous,matched sibling,andalternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study

2024.03.19
In September 2023, a pivotal study led by professor Erlie Jiang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science was published in Hematology, focusing on acute myeloid leukemia (AML) patients in their first remission and comparing outcomes between autologous, matched sibling, and alternative donor stem cell transplants. This research innovatively applied propensity score matching to dissect and evaluate the nuances of transplant efficacy and safety across different donor types. By conducting a thorough and detailed comparison, Jiang and her collaborative team have markedly advanced the understanding of optimal transplant strategies for AML treatment. Their work illuminates the path toward enhancing patient survival rates and quality of life through informed donor selection, underscoring the study’s significance in the realm of personalized AML care. Through this study, Erlie Jiang and her colleagues have made a substantial contribution to refining clinical decision-making in the selection of stem cell transplant donors for AML patients.